High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV), potentially useful to monitor the effect of treatments in this disease. In a phase 2 study of pegylated (peg) IFN-alpha-2a in PV, we performed prospective sequential quantitative evaluation of the percentage of mutated JAK2 allele (%V617F) by real-time polymerase chain reaction (PCR). The %V617F decreased in 24 (89%) of 27 treated patients, from a mean of 49% to a mean of 27% (mean decrease of 44%; P < .001), and no evidence for a plateau was observed. In one patient, mutant JAK2 was no longer detectable after 12 months. In 3 patients homozygous for the mutation, reappearance of 50% of wild-type allele was observed during treatment. The results seem to confirm the hypothesis that IFN-alpha preferentially targets the malignant clone in PV and show that %V617F assessment using a quantitative method may provide the first tool to monitor minimal residual disease in PV. This trial was registered at www.clinicaltrials.gov as #NCT00241241.

[1]  M. Cazzola,et al.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.

[2]  W. Vainchenker,et al.  Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis , 2006, Leukemia.

[3]  D. Oscier,et al.  Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. , 2005, Blood.

[4]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[5]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[6]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[7]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[8]  W. Vainchenker,et al.  A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. , 2005, Hematology. American Society of Hematology. Education Program.

[9]  M. Griesshammer,et al.  Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. , 2005, Haematologica.

[10]  D. Oscier,et al.  The Optimal Management of Polycythaemia Vera , 2003, British journal of haematology.

[11]  R. Bukowski,et al.  Treating cancer with PEG Intron , 2002, Cancer.

[12]  Z. Estrov,et al.  Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia , 2002, Cancer Chemotherapy and Pharmacology.

[13]  C. Perry,et al.  Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. , 2001, Drugs.

[14]  B. Sikic.  Pharmacologic approaches to reversing multidrug resistance. , 1997, Seminars in hematology.

[15]  C. Clerici,et al.  Polycythemia vera treated with recombinant interferon‐alpha 2a: Evidence of a selective effect on the malignant clone , 1997, American journal of hematology.

[16]  J. Schifferli,et al.  Paraproteins and complement depletion: pathogenesis and clinical syndromes. , 1997, Seminars in hematology.

[17]  R. Silver,et al.  Interferon alfa: effects of long-term treatment for polycythemia vera. , 1997, Seminars in hematology.

[18]  S. Sacchi,et al.  Cytogenetic conversion in a case of polycythaemia vera treated with interferon‐alpha , 1994, British journal of haematology.

[19]  S. Schwartz.  Myeloproliferative Disorders , 1975, Annals of surgery.